Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of tildrakizumab in psoriatic arthritis
2018-001060-35Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tildrakizumab in psoriatic arthritis (PsA), sponsored by Sun Pharma. Started Jun 2018; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-001060-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001060-35.